Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 175

The DOI matches its Crossref record.

Duloxetine for the Treatment of Major Depressive Disorder

Nemeroff, Charles B., MD, PhD, Schatzberg, Alan F., MD, Goldstein, David J., MD, PhD, Detke, Michael J., MD, PhD, Mallinckrodt, Craig, PhD, Lu, Yili, PhD, Tran, and Pierre V., MD · 2025 · Psychopharmacology Bulletin

Abstract

Background. Existing therapies for depression frequently fail to provide full remission. This report evaluates the efficacy and safety of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine, in the treatment of major depressive disorder (MDD). Method. Efficacy of duloxetine was evaluated in six double-blind, placebo- and/or active-comparator-controlled clinical trials. A study of duloxetine in patients with stress urinary incontinence was also included in the safety assessments. The primary efficacy measure was total score on the 17-item Hamilton Rating Scale for Depression (HAMD-17). Secondary measures included estimated probabilities of response and remission, and changes in the Clinical Global Impressions scale, Patients Global Impression scale, and the Hamilton Rating Scale for Anxiety. Physical symptoms were assessed using Visual Analog Scales for Pain. Safety evaluations included reporting of adverse events, changes in vital signs, electrocardiogram, blood pressure, and laboratory analyses. Results. Duloxetine was significantly superior to placebo in reducing mean HAMD-17 total score in four of the six studies. Significant improvements for duloxetine over placebo were also observed on many secondary efficacy measures across five of the studies. Probabilities of remission >55% were observed in two of the studies, while in a third study the probability of remission with duloxetine treatment was nearly three times that observed with placebo (44% versus 16%). Duloxetine also produced significant improvement in painful physical symptoms compared with placebo, in many cases after only 2 weeks of treatment. The discontinuation rate due to adverse events (14.6%) was similar to those observed with selective serotonin reuptake inhibitors. The most frequently reported adverse events were nausea, dry mouth, fatigue, and insomnia. Conclusion. Duloxetine was demonstrated to be safe and effective in the treatment of MDD. The starting dose with the best balance of efficacy and tolerability is 60 mg per day. Psychopharmacology Bulletin. 2002;36(4):106-132

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.64719/pb.4207

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 175

Metadata

Authors
Nemeroff, C. B., MD, PhD, Schatzberg, A. F., MD, Goldstein, D. J., MD, PhD, Detke, M. J., MD, PhD, Mallinckrodt, C., PhD, Lu, Y., PhD, Tran, A. P. V., & MD
Venue
Psychopharmacology Bulletin
Published
2025-08-12
Volume
36
Issue
4
Pages
106-132
ISSN
  • 0048-5764 (ISSN-L)
  • 2472-2448
OpenAlex
W72273208
Cited by
175
References
0
FWCI
2.43
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Duloxetine for the Treatment of Major Depressive Disorder. https://app.cochat.ai/papers/10.64719/pb.4207
The paper
Nemeroff, C. B., MD, PhD, Schatzberg, A. F., MD, Goldstein, D. J., MD, PhD, Detke, M. J., MD, PhD, Mallinckrodt, C., PhD, Lu, Y., PhD, Tran, A. P. V., & MD. (2025). Duloxetine for the Treatment of Major Depressive Disorder. Psychopharmacology Bulletin. https://doi.org/10.64719/pb.4207

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.